Navigation Links
Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
Date:6/30/2009

SAN DIEGO, June 30 /PRNewswire/ -- Accumetrics, Inc. announces that it has reached the halfway mark (1,600 patients) in the enrollment of its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay Impact on Thrombosis And Safety). The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for patients who are poor responders to clopidogrel (Plavix(R)). The multi-center, placebo controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on the results of the company's VerifyNow P2Y12 Test, reduces major cardiovascular adverse events (e.g., heart attack, stent thrombosis) following percutaneous coronary intervention (PCI). Currently the trial is being conducted at more than 70 sites in the U.S. and Canada, with a total enrollment goal of approximately 2,800 patients.

"We are thrilled to have reached the halfway point for enrollment in our GRAVITAS trial," said Jeff Dahlen, Ph.D, Vice President, Clinical and Regulatory Affairs of Accumetrics, Inc. "Once complete, GRAVITAS will be the largest multi-center clinical trial that links testing with personalized medicine and improved patient outcomes. We continue our commitment to ensuring that the VerifyNow System is shown to be an integral tool in optimizing the use of antiplatelet therapy."

About GRAVITAS

The concept of variability in response to antiplatelet therapy has been well established. Also being demonstrated with increased frequency is the question of whether poor response to antiplatelet therapy, based on a laboratory test, leads to poor patient outcomes. However, Accumetrics recognizes the need for a study specifically designed to demonstrate the value of providing clinicians with actionable information to improve outcomes for those patients who are poor responders to antip
'/>"/>

SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
2. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
3. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
4. Innovative Psoriasis Treatment PSORENT(R) Announces Healthcare Cost Savings Potential Consistent with President Obamas Announcement on Healthcare Reform
5. ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases
6. Spherix Announces Positive Phase 2 Study Results
7. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
8. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
9. CoAxia, Inc. Announces $21.5M Series D Financing
10. Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
11. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...-FirstCall/ -- Escalon Medical Corp. (Nasdaq Marke...t quarter ended September 30, 2009. ,, For th...creased approximately $234,000, or 2.7%, to $8,435... 30, 2009 as compared to the same period last fisc...evenue of $8,434,000 compared with $8,669,000 in f...
(Date:11/20/2009)...wire-FirstCall/ -- Landauer, Inc. ( LDR) , wi... quarter and full year of 2009 pre-market on Tuesd...a conference call for investors on Tuesday, Decemb...ay access the live call by dialing 877-941-9205 (w...35 (international callers), or by visiting the "In...
(Date:11/20/2009)...ire/ -- Reportlinker.com announces that a new mark...,, Pipettes & Pipettors - A Global Market ...0164373/Pipettes--Pipettors---A-Global-Market-Pers...pr&utm_campaign=prnewswire ,, Pipettes an... research laboratory. Large-scale applications in ...
Breaking Medicine Technology:Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Cleveland Lawyers Recognized by Peers on The Best Lawyers in America List 57298 1Cleveland Lawyers Recognized by Peers on The Best Lawyers in America List 57298 2Cleveland Lawyers Recognized by Peers on The Best Lawyers in America List 57298 3Implementing QA Automation Tools in an FDA Controlled Software Environment a Free Webinar 14071 1Implementing QA Automation Tools in an FDA Controlled Software Environment a Free Webinar 14071 2Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 14069 1Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 14069 2
...itional protection against,infection with virus ty...candidate vaccine, PHILADELPHIA, June 27, 2007 /PR...lysis of a Phase III study show that,CERVARIX(R), ...ine,provides up to 100 percent protection against...common types of human papillomavirus,types 16 and...
... with VELCADE, cyclophosphamide,and prednisone al...ewswire-FirstCall/ -- Millennium,Pharmaceuticals, ...,from clinical trials of VELCADE based therapies t...onse(1) (CR) rates in previously,treated multiple ...ed at the prestigious 11th International Myeloma W...
Other Medicine Technology:Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 2Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 3Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 4Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 5Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 6Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 7Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 2Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 3Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 4Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 5Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 6
(Date:11/21/2009)... Nov. 21 A regional ini...rciasis (river blindness) in the Americas has subs... recent years, as evidenced by a 31% decrease in t...istration in six endemic countries. Results were ...merican Society of Tropical Medicine and Hygiene (...
(Date:11/21/2009)... NH based medical credentialing software company ...form a partnerhsip with Amerinet, Inc., the leadin...will help to transform quality care within the hea... November 21, 2009 -- ISG Group, LLC, doing busine...ment with Amerinet Inc., a leading national health...
(Date:11/21/2009)... Eric J. Hall, president and chief executive offi... issued the following statement regarding the incl... the new annual wellness for Medicare beneficiarie...are Act" that was introduced last night: , ...er 21, 2009 -- Eric J. Hall, president and chief e...
(Date:11/20/2009)...urologist Closer to Understanding Brain Wiring and...Newswire/ -- Dr. Jeremy Schmahmann, Professor of N... at the Massachusetts General Hospital in Boston, ...,s research on the new field of study called "Conn.... ,, Dr. Schmahmann is an award-winning leader ...
(Date:11/20/2009)...ON, Nov. 20 The United ...nate to make essential changes its health reform b...ion funding and conscience protection on abortion,...include strong provisions for adequate affordabili...e bill an "enormous disappointment" that creates n...
Breaking Medicine News(10 mins):Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2
...UVER, Feb. 24 /PRNewswire-FirstCall/ - CRH Medical...nership Program, the CRH O,Regan Hemorrhoid bandin...the gastroenterologist practice groups trained by ...ency of its training methodology. The sharing of k...
...EATTLE, Feb. 24, 2009 As Zimbabwe continues to co...d sanitation infrastructure, a new,World Vision pr... PG ) Children,s,Safe Drinking Water Program is ...://www.newscom.com/cgi-bin/prnh/20090115/CLTH035LO...
...NGTON, Feb. 24 As genetic tests become more affor...nalized medical information that can help them man...ion and treatment. But not all genetic tests are c...ican Clinical Laboratory Association and its educa...
...inds better concentration, lowered stress after,TM...News) -- Meditation might help protect college stu...learn, suggests a study that examined the effects ...nderwent physiological and psychological tests and...
...ce uses search engine optimization and individuali...h Yellow Page ads , , ST. LOUIS, Feb. 24 Creativ...he launch of My Hometown Vet , a cost-effective w... Hometown Vet uses a combination of search engine ...
...LISO VIEJO, Calif., Feb. 24 Valeant,Pharmaceutica...urth quarter and,full year financial results for 2...inning to take hold in the fourth,quarter, we cont...r future revenue and cash flow potential by acquir...
Other Medicine News:Health News:CRH provides Partnership Program update 2Health News:Procter & Gamble and World Vision Equip and Empower Zimbabweans in Fight Against Cholera 2Health News:Procter & Gamble and World Vision Equip and Empower Zimbabweans in Fight Against Cholera 3Health News:Six Questions Consumers Should Ask About Genetic Tests 2Health News:Meditation May Boost College Students' Learning 2Health News:Creative Marketing Solutions Launches My Hometown Vet, Giving Veterinary Practices Better Visibility Online 2Health News:Creative Marketing Solutions Launches My Hometown Vet, Giving Veterinary Practices Better Visibility Online 3Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 2Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 3Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 4Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 5Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 6Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 7Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 8Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 9Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 10Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 11Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 12Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 13Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 14Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 15Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 16Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 17Health News:Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results 18
8.50mm diameter Corneal Trephine Blades
8.00mm diameter Corneal Trephine Blades
7.85mm diameter Corneal Trephine Blades
7.25mm diameter Corneal Trephine Blades
Medicine Products: